Skip to main content
Premium Trial:

Request an Annual Quote

University of Miami to Study BRCA Rates in Caribbean Women

NEW YORK (GenomeWeb News) – A University of Miami researcher has reeled in a $600,000 grant from the Susan G. Komen for the Cure Foundation to study the genetic characteristics of breast cancer in women in the Caribbean.

The research will study the genetic characteristics of 1,000 breast cancer patients from four Caribbean countries by searching for the BRCA1 and BRCA2 genes, which are found in 23 percent of women with breast cancer in the Bahamas — the highest rate in the world — compared with three to five percent in the US.

"In order to further investigate this we will offer free genetic testing and counseling to women of Trinidad and Tobago, Barbados, the Cayman Islands and Dominica who have breast or ovarian cancer," principal investigator Judith Hurley, an associate professor of clinical medicine and medical director of the Hematology/Oncology Clinics at Jackson Memorial Hospital, told GenomeWeb Daily News in an e-mail.

"This research may lead to a better understanding of issues unique to black women throughout the Caribbean and in the US, as we attempt to address breast cancer's impacts across diverse groups," Komen President Elizabeth Thompson said in a statement.

This research is a collaboration with Women's College Hospital in Toronto, Hurley said.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.